GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome

There is no fulltext present in this item.

Title:	GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome
Author(s):	Botezatu, L.; Michel, L.C.; Makishima, H.; Schroeder, T.; Germing, U.; Haas, R; Reijden, B.A. van der ; Marneth, A.E.; Bergevoet, S.M. ; Jansen, J.H. ; Przychodzen, B.; Wlodarski, M.; Niemeyer, C.; Platzbecker, U.; Ehninger, G.; Unnikrishnan, A.; Beck, D.; Pimanda, J.; Hellström-Lindberg, E.; Malcovati, L.; Boultwood, J.; Pellagatti, A.; Papaemmanuil, E.; Coutre, P. Le; Kaeda, J.; Opalka, B.; Möröy, T.; Dührsen, U.; Maciejewski, J; Khandanpour, C.
Publication year:	2016
Source:	Experimental Hematology, vol. 44, iss. 7, (2016), pp. 590-595
ISSN:	0301-472X
DOI:	https://doi.org/10.1016/j.exphem.2016.04.001
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/172597
Display more details
Subject:	Radboudumc 2: Cancer development and immune defence RIMLS: Radboud Institute for Molecular Life Sciences
Organization:	Laboratory Medicine
Journal title:	Experimental Hematology
Volume:	vol. 44
Issue:	iss. 7
Page start:	p. 590
Page end:	p. 595